精彩内容7月1日,新华制药发布《药品补充申请批准通知书》公告,马来酸阿伐曲泊帕片上市许可持有人由上海迪赛诺医药变更为新华制药。米内网数据显示,马来酸阿伐曲泊帕片在2023年中国三大终端六大市场(统计范围详见本文末)销售额突破10亿元大关,2024年再度增长2.26%,是止血药(化+生)TOP5产品。马来酸阿伐曲泊帕片适用于择期行诊断性操作或者手术的慢性肝病相关血小板减少症的成年患者;慢性肝病患者...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.